BAKER BROS. ADVISORS LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001263508
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2026 · 83 positions · Total reported value $19.13B · Top-10 concentration 74.7% · Updated 2026-10-24
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
Turnover: 24.2% · 8 new · 6 cut · 8 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +14.7% · vs SPY -0.1% · Prev Value $16.51B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2026 13F filing, BAKER BROS. ADVISORS LP disclosed 83 equity positions with a combined reported value of $19.13B. The filing implies a focused portfolio: its ten largest positions account for 74.7% of reported value. HoldingsHub classifies the profile as Large / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2026 were INCY ($3.49B), ONC ($2.51B), RVMD ($2.14B). By sector, the heaviest allocations are Health Care 99.4%, Other 0.6%.
Versus the prior quarter, BAKER BROS. ADVISORS LP opened 8 new positions, trimmed 6 and fully exited 8, a turnover rate of 24.2% of positions. The portfolio's overlap with the prior quarter was 82% of names.
The largest new positions opened in Q2 2026 were FTH ($32.16M), CYTK ($18.00M), NTLA ($15.74M).
Of the 8 positions fully exited versus the prior quarter, the largest were ABVX ($97.52M), SYRE ($50.44M), CNTA ($26.64M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2026)
- FTH FAETH THERAPEUTICS INC · $32.16M
- CYTK CYTOKINETICS INC · $18.00M
- NTLA INTELLIA THERAPEUTICS INC · $15.74M
- PBLS PARABILIS MEDICINES INC · $13.69M
- AVLN AVALYN PHARMA INC · $11.52M
- TNGX TANGO THERAPEUTICS INC · $10.42M
- AVTX AVALO THERAPEUTICS INC · $10.16M
- IMNM IMMUNOME INC · $1.17M
Fully Exited (vs previous quarter)
- ABVX ABIVAX SA · prev qtr: $97.52M
- SYRE SPYRE THERAPEUTICS INC · prev qtr: $50.44M
- CNTA CENTESSA PHARMACEUTICALS PLC · prev qtr: $26.64M
- IMCR IMMUNOCORE HLDGS PLC · prev qtr: $22.14M
- CTNM CONTINEUM THERAPEUTICS INC A · prev qtr: $18.56M
- ARGX ARGENX SE · prev qtr: $18.38M
- CMPS COMPASS PATHWAYS · prev qtr: $12.97M
- PHVS PHARVARIS NV · prev qtr: $10.59M
Insider Transactions (Form 4)
Latest BAKER BROS. ADVISORS LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-11-06 | Buy | MADRIGAL PHARMACEUTICALS, INC. | 2,000 | $396.61 | SEC filing |
| 2026-11-06 | Buy | MADRIGAL PHARMACEUTICALS, INC. | 13,740 | $388.29 | SEC filing |
| 2026-11-06 | Buy | MADRIGAL PHARMACEUTICALS, INC. | 60,400 | $383.01 | SEC filing |
| 2026-11-05 | Buy | Kodiak Sciences Inc. | 81,729 | $98.51 | SEC filing |
| 2026-11-05 | Buy | Kodiak Sciences Inc. | 4,703 | $98.51 | SEC filing |
| 2026-11-04 | Buy | Kodiak Sciences Inc. | 151,916 | $98.51 | SEC filing |
| 2026-11-04 | Buy | Kodiak Sciences Inc. | 8,742 | $98.51 | SEC filing |
| 2026-11-04 | Buy | MADRIGAL PHARMACEUTICALS, INC. | 10,080 | $368.11 | SEC filing |
Fund Profile
Baker BROS. Advisors is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 83 US equity positions with a combined value of $19.13B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-73446 (status: Approved), registered 2012-03-05
- Regulatory AUM (Form ADV): $28.15B as of 2026-03-27
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 2 private funds, of which 2 hedge funds
Portfolio Structure
- 83 positions · $19.13B reported value (Q2 2026)
- Top 10 holdings = 74.7% of reported value
- Largest position: INCY (INCYTE CORP) at 18.2%
- Average position size: $230.45M
Sector Tilt
- Health Care 99.4%
- (classified holdings cover 99% of value)
Quarterly Activity
- Q2 2026: 8 new, 10 added, 6 reduced, 8 exited
- 59 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
30.76M | $3.49B | 18.23% Form 4 · 1 → |
Hold | |
| 2 |
|
8.80M | $2.51B | 13.11% Form 4 · 1 → |
Hold | |
| 3 |
|
11.44M | $2.14B | 11.21% | Add | |
| 4 |
|
2.14M | $1.15B | 6.02% Form 4 · 5 → |
Hold | |
| 5 |
|
42.91M | $1.09B | 5.68% | Hold | |
| 6 |
|
8.66M | $992.73M | 5.19% | Hold | |
| 7 |
|
8.80M | $937.84M | 4.90% | Add | |
| 8 |
|
19.92M | $776.05M | 4.06% Form 4 · 86 → |
Hold | |
| 9 |
|
5.60M | $622.27M | 3.25% | Hold | |
| 10 |
|
1.75M | $586.95M | 3.07% | Hold | |
| 11 |
|
10.01M | $524.59M | 2.74% | Hold | |
| 12 |
|
32.79M | $477.70M | 2.50% | Reduce | |
| 13 |
|
4.03M | $275.03M | 1.44% | Hold | |
| 14 |
|
33.01M | $259.15M | 1.35% | Add | |
| 15 |
|
5.44M | $209.42M | 1.09% | Hold | |
| 16 |
|
5.01M | $186.72M | 0.98% | Add | |
| 17 |
|
2.83M | $181.28M | 0.95% | Hold | |
| 18 |
|
4.72M | $166.93M | 0.87% | Reduce | |
| 19 |
|
1.99M | $162.43M | 0.85% | Hold | |
| 20 |
|
2.05M | $162.36M | 0.85% | Hold | |
| 21 |
|
3.70M | $150.40M | 0.79% | Reduce | |
| 22 |
|
11.05M | $122.27M | 0.64% | Hold | |
| 23 |
|
4.66M | $113.02M | 0.59% | Hold | |
| 24 |
|
3.34M | $109.18M | 0.57% | Hold | |
| 25 |
|
4.35M | $105.17M | 0.55% | Hold | |
| 26 |
|
9.51M | $96.32M | 0.50% | Reduce | |
| 27 |
|
3.73M | $96.05M | 0.50% | Hold | |
| 28 |
|
2.35M | $87.99M | 0.46% | Hold | |
| 29 |
|
852.16K | $83.07M | 0.43% | Hold | |
| 30 |
|
1.43M | $76.88M | 0.40% | Hold | |
| 31 |
|
30.75M | $69.16M | 0.36% | Hold | |
| 32 |
|
1.55M | $64.47M | 0.34% | Hold | |
| 33 |
|
2.01M | $56.63M | 0.30% | Hold | |
| 34 |
|
10.12M | $53.96M | 0.28% | Hold | |
| 35 |
|
2.83M | $52.89M | 0.28% | Add | |
| 36 |
|
445.98K | $52.21M | 0.27% | Hold | |
| 37 |
|
10.89M | $46.15M | 0.24% | Hold | |
| 38 |
|
905.19K | $45.94M | 0.24% | Hold | |
| 39 |
|
1.18M | $44.00M | 0.23% | Add | |
| 40 |
|
2.38M | $43.78M | 0.23% | Add | |
| 41 |
|
2.68M | $38.76M | 0.20% | Add | |
| 42 |
|
5.07M | $37.34M | 0.20% | Hold | |
| 43 |
|
1.29M | $32.16M | 0.17% | New | |
| 44 |
|
996.35K | $32.11M | 0.17% | Hold | |
| 45 |
|
991.69K | $31.19M | 0.16% | Hold | |
| 46 |
|
1.23M | $27.34M | 0.14% | Reduce | |
| 47 |
|
4.00M | $27.27M | 0.14% | Hold | |
| 48 |
|
844.82K | $26.05M | 0.14% | Add | |
| 49 |
|
349.66K | $25.57M | 0.13% | Hold | |
| 50 |
|
2.13M | $24.74M | 0.13% | Hold | |
Loading forecast…
Holdings Prediction Model
Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.
The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.
Latest-Quarter Accuracy (2026-Q2)
P 90% R 90% F1 90% (modelled on 2026-Q1; 9/10 hit)
Historical Backtest (10 quarters)
Avg precision 91% · recall 91% · F1 91% · avg rank error 1.0 · Top-10 turnover 12%
| Quarter | Prec. | Recall | F1 | Predicted Top 10 | Actual Top 10 |
|---|---|---|---|---|---|
| 2024-Q1 | 80% | 80% | 80% | INCY · ONC · ACAD · MDGL · RYTM · MRTX · IMCR · RVMD · KYMR · ABCL | INCY · ONC · ACAD · MDGL · RYTM · RVMD · KYMR · ABCL · BCYC · EWTX |
| 2024-Q2 | 80% | 80% | 80% | INCY · ONC · ACAD · MDGL · RVMD · RYTM · KYMR · BCYC · ABCL · EWTX | INCY · ONC · ACAD · MDGL · RVMD · RYTM · INSM · BCYC · SMMT · KYMR |
| 2024-Q3 | 100% | 100% | 100% | INCY · ONC · ACAD · MDGL · RVMD · INSM · RYTM · BCYC · SMMT · KYMR | ONC · INCY · ACAD · SMMT · MDGL · RVMD · RYTM · INSM · KYMR · BCYC |
| 2024-Q4 | 90% | 90% | 90% | ONC · INCY · ACAD · SMMT · MDGL · INSM · RVMD · RYTM · KYMR · BCYC | INCY · ONC · ACAD · MDGL · SMMT · RVMD · INSM · RYTM · KYMR · KOD |
| 2025-Q1 | 90% | 90% | 90% | INCY · ONC · ACAD · MDGL · SMMT · INSM · RVMD · RYTM · KYMR · KOD | ONC · INCY · ACAD · MDGL · SMMT · INSM · RYTM · RVMD · KYMR · ALKS |
| 2025-Q2 | 100% | 100% | 100% | ONC · INCY · ACAD · MDGL · SMMT · INSM · RYTM · RVMD · KYMR · ALKS | ONC · INCY · ACAD · INSM · SMMT · MDGL · RYTM · RVMD · KYMR · ALKS |
| 2025-Q3 | 90% | 90% | 90% | INCY · ONC · ACAD · INSM · SMMT · MDGL · RVMD · RYTM · KYMR · ALKS | ONC · INCY · MDGL · INSM · ACAD · SMMT · RYTM · RVMD · KYMR · KOD |
| 2025-Q4 | 100% | 100% | 100% | ONC · INCY · INSM · MDGL · ACAD · SMMT · RYTM · RVMD · KYMR · KOD | INCY · ONC · MDGL · INSM · ACAD · RVMD · KYMR · SMMT · RYTM · KOD |
| 2026-Q1 | 90% | 90% | 90% | INCY · ONC · MDGL · ACAD · INSM · RVMD · KYMR · SMMT · RYTM · KOD | INCY · ONC · INSM · MDGL · ACAD · RVMD · KOD · KYMR · SMMT · PRAX |
| 2026-Q2 ★ | 90% | 90% | 90% | INCY · ONC · INSM · MDGL · ACAD · RVMD · KOD · KYMR · SMMT · PRAX | INCY · ONC · RVMD · MDGL · ACAD · KYMR · INSM · KOD · RYTM · PRAX |
★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.
FAQ
What did BAKER BROS. ADVISORS LP buy in 2026-Q2?
In its 2026-Q2 13F filing, BAKER BROS. ADVISORS LP reported 83 equity positions worth $19.13B in aggregate; its largest disclosed positions were INCY ($3.49B), ONC ($2.51B), RVMD ($2.14B).
How large is BAKER BROS. ADVISORS LP's portfolio?
BAKER BROS. ADVISORS LP reported $19.13B of long equity holdings across 83 positions as of 2026-Q2. Top-10 holdings account for 74.7% of reported value.
What is BAKER BROS. ADVISORS LP's investment style?
HoldingsHub classifies the portfolio as Large / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.